25006961|t|Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus.
25006961|a|Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus (NDI) in  40% of patients. The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing urea transporter (UT-A1) and water channel (AQP2) expression in the inner medulla. Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced polyuria. PKC-alpha null mice (PKCa KO) and strain-matched wild type (WT) controls were treated with lithium for 0, 3 or 5 days. WT mice had increased urine output and lowered urine osmolality after 3 and 5 days of treatment whereas PKCa KO mice had no change in urine output or concentration. Western blot analysis revealed that AQP2 expression in medullary tissues was lowered after 3 and 5 days in WT mice; however, AQP2 was unchanged in PKCa KO. Similar results were observed with UT-A1 expression. Animals were also treated with lithium for 6 weeks. Lithium-treated WT mice had 19-fold increased urine output whereas treated PKCa KO animals had a 4-fold increase in output. AQP2 and UT-A1 expression was lowered in 6 week lithium-treated WT animals whereas in treated PKCa KO mice, AQP2 was only reduced by 2-fold and UT-A1 expression was unaffected. Urinary sodium, potassium and calcium were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.
25006961	11	20	PKC-alpha	GeneOrGeneProduct	18750
25006961	32	39	lithium	ChemicalEntity	D008094
25006961	48	78	nephrogenic diabetes insipidus	DiseaseOrPhenotypicFeature	D018500
25006961	80	87	Lithium	ChemicalEntity	D008094
25006961	125	155	nephrogenic diabetes insipidus	DiseaseOrPhenotypicFeature	D018500
25006961	157	160	NDI	DiseaseOrPhenotypicFeature	D018500
25006961	173	181	patients	OrganismTaxon	9606
25006961	244	251	lithium	ChemicalEntity	D008094
25006961	275	279	cAMP	ChemicalEntity	D000242
25006961	313	329	urea transporter	GeneOrGeneProduct	27411
25006961	331	336	UT-A1	GeneOrGeneProduct	27411
25006961	357	361	AQP2	GeneOrGeneProduct	11827
25006961	448	451	PKC	GeneOrGeneProduct	18750
25006961	511	518	lithium	ChemicalEntity	D008094
25006961	527	535	polyuria	DiseaseOrPhenotypicFeature	D011141
25006961	537	546	PKC-alpha	GeneOrGeneProduct	18750
25006961	552	556	mice	OrganismTaxon	10090
25006961	558	562	PKCa	GeneOrGeneProduct	18750
25006961	628	635	lithium	ChemicalEntity	D008094
25006961	659	663	mice	OrganismTaxon	10090
25006961	760	764	PKCa	GeneOrGeneProduct	18750
25006961	768	772	mice	OrganismTaxon	10090
25006961	857	861	AQP2	GeneOrGeneProduct	11827
25006961	931	935	mice	OrganismTaxon	10090
25006961	946	950	AQP2	GeneOrGeneProduct	11827
25006961	968	972	PKCa	GeneOrGeneProduct	18750
25006961	1012	1017	UT-A1	GeneOrGeneProduct	27411
25006961	1061	1068	lithium	ChemicalEntity	D008094
25006961	1082	1089	Lithium	ChemicalEntity	D008094
25006961	1101	1105	mice	OrganismTaxon	10090
25006961	1157	1161	PKCa	GeneOrGeneProduct	18750
25006961	1206	1210	AQP2	GeneOrGeneProduct	11827
25006961	1215	1220	UT-A1	GeneOrGeneProduct	27411
25006961	1254	1261	lithium	ChemicalEntity	D008094
25006961	1300	1304	PKCa	GeneOrGeneProduct	18750
25006961	1308	1312	mice	OrganismTaxon	10090
25006961	1314	1318	AQP2	GeneOrGeneProduct	11827
25006961	1350	1355	UT-A1	GeneOrGeneProduct	27411
25006961	1391	1397	sodium	ChemicalEntity	D012964
25006961	1399	1408	potassium	ChemicalEntity	D011188
25006961	1413	1420	calcium	ChemicalEntity	D002118
25006961	1438	1445	lithium	ChemicalEntity	D008094
25006961	1464	1471	lithium	ChemicalEntity	D008094
25006961	1476	1480	PKCa	GeneOrGeneProduct	18750
25006961	1484	1488	mice	OrganismTaxon	10090
25006961	1521	1525	PKCa	GeneOrGeneProduct	18750
25006961	1536	1540	AQP2	GeneOrGeneProduct	11827
25006961	1545	1550	UT-A1	GeneOrGeneProduct	27411
25006961	1590	1597	lithium	ChemicalEntity	D008094
25006961	1606	1609	NDI	DiseaseOrPhenotypicFeature	D018500
25006961	1654	1662	polyuria	DiseaseOrPhenotypicFeature	D011141
25006961	1679	1686	lithium	ChemicalEntity	D008094
25006961	Association	D002118	D008094	Novel
25006961	Negative_Correlation	27411	D008094	Novel
25006961	Association	D011141	18750	Novel
25006961	Negative_Correlation	11827	18750	Novel
25006961	Association	D008094	D011188	Novel
25006961	Association	D008094	D012964	Novel
25006961	Positive_Correlation	D008094	D011141	No
25006961	Negative_Correlation	D008094	11827	Novel
25006961	Positive_Correlation	D008094	D018500	Novel
25006961	Negative_Correlation	18750	27411	Novel
25006961	Positive_Correlation	18750	D008094	Novel
25006961	Positive_Correlation	18750	D018500	Novel